These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 2282861

  • 1. [Tumor markers in the monitoring of ovarian cancer].
    Xu SX.
    Zhonghua Fu Chan Ke Za Zhi; 1990 Nov; 25(6):345-7, 383. PubMed ID: 2282861
    [Abstract] [Full Text] [Related]

  • 2. [Serum lipid-associated sialic acid (LSA) in diagnosing and monitoring ovarian cancer].
    Yue K, Bian M, Zhu D, Liu W, Siu S.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1995 Apr; 17(2):128-32. PubMed ID: 7656393
    [Abstract] [Full Text] [Related]

  • 3. Plasma lipid-associated sialic acid and serum CA 125 as indicators of disease status with advanced ovarian cancer.
    Vardi JR, Tadros GH, Foemmel R, Shebes M.
    Obstet Gynecol; 1989 Sep; 74(3 Pt 1):379-83. PubMed ID: 2761915
    [Abstract] [Full Text] [Related]

  • 4. Tumor markers in epithelial ovarian cancer. Clinical applications.
    Hempling RE.
    Obstet Gynecol Clin North Am; 1994 Mar; 21(1):41-61. PubMed ID: 8015766
    [Abstract] [Full Text] [Related]

  • 5. The significance of neopterin determination as a tumour marker in ovarian cancer.
    Szarka G, Pulay T, Csömör S, Tran-Phoung-Mai, Schumann B.
    Acta Chir Hung; 1988 Mar; 29(4):359-64. PubMed ID: 3239335
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Serum lipid-bound sialic acid as a marker in lung cancer patients].
    Iwahashi N.
    Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Dec; 28(12):1599-607. PubMed ID: 2077205
    [Abstract] [Full Text] [Related]

  • 8. The importance of polyamine determination in monitoring malignant gynaecological tumours.
    Szarka G, Pulay T, Csömör S, Tran-Phuong-Mai, Schumann B.
    Acta Chir Hung; 1988 Dec; 29(4):365-72. PubMed ID: 3239336
    [Abstract] [Full Text] [Related]

  • 9. CA54/61 as a marker for epithelial ovarian cancer.
    Nozawa S, Aoki D, Yajima M, Tsukazaki K, Kobayashi T, Kimura E, Terashima Y, Inaba N, Takamizawa H, Negishi Y.
    Cancer Res; 1992 Mar 01; 52(5):1205-9. PubMed ID: 1737381
    [Abstract] [Full Text] [Related]

  • 10. [The usefulness and limitation of sugar antigen in ovarian cancers--with special reference to a new tumor marker, CA54/61].
    Nozawa S.
    Gan To Kagaku Ryoho; 1989 Apr 01; 16(4 Pt 2-1):1147-51. PubMed ID: 2499263
    [Abstract] [Full Text] [Related]

  • 11. Serum and tissue measurements of CA72-4 in ovarian cancer patients.
    Negishi Y, Iwabuchi H, Sakunaga H, Sakamoto M, Okabe K, Sato H, Asano G.
    Gynecol Oncol; 1993 Feb 01; 48(2):148-54. PubMed ID: 8381375
    [Abstract] [Full Text] [Related]

  • 12. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.
    Cane P, Azen C, Lopez E, Platt LD, Karlan BY.
    Gynecol Oncol; 1995 May 01; 57(2):240-5. PubMed ID: 7729742
    [Abstract] [Full Text] [Related]

  • 13. [Study of the mechanism of tumor marker CA125 in serum].
    Kiyozuka Y, Noda T, Adachi S, Adachi S, Akada S, Ichijo M.
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec 01; 41(12):1951-8. PubMed ID: 2592818
    [Abstract] [Full Text] [Related]

  • 14. Serum sialic acid (TSA/LSA) and carcinoembryonic antigen (CEA) levels in cancer patients undergoing radiotherapy.
    Stringou E, Chondros K, Kouvaris J, Kakari S, Papavassiliou K.
    Anticancer Res; 1992 Dec 01; 12(1):251-5. PubMed ID: 1567173
    [Abstract] [Full Text] [Related]

  • 15. [The clinical significance of CA125 in patients with gynecological tumors--a comparative study on CA125 and other tumor markers].
    Suzumori K, Yasui Y, Asai H, Hisaoka T, Mizuno K, Yagami Y.
    Gan No Rinsho; 1985 May 01; 31(5):544-8. PubMed ID: 3860666
    [Abstract] [Full Text] [Related]

  • 16. [Clinical value of a new serum tumor marker CA602 in ovarian cancers].
    Suzuki M, Sekiguchi I, Ohwada M, Aida I, Tamada T.
    Nihon Gan Chiryo Gakkai Shi; 1990 Jul 20; 25(7):1454-60. PubMed ID: 2170549
    [Abstract] [Full Text] [Related]

  • 17. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L, Cui H, Li XP, Sun LF, Chang XH, Liang XD, Zhu HL.
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan 20; 43(1):5-8. PubMed ID: 18366923
    [Abstract] [Full Text] [Related]

  • 18. Relationship of serum CA125 and lipid-associated sialic acid tumor-associated antigen levels to the disease status of patients with gynecologic malignancies.
    Stratton JA, Rettenmaier MA, Phillips HB, Herabutya S, DiSaia PJ.
    Obstet Gynecol; 1988 Jan 20; 71(1):20-6. PubMed ID: 2827081
    [Abstract] [Full Text] [Related]

  • 19. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
    Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC.
    Gynecol Oncol; 2008 Feb 20; 108(2):402-8. PubMed ID: 18061248
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of CA125 as a circulating tumor marker for ovarian cancer.
    Kuzuya K, Nozaki M, Chihara T.
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun 20; 38(6):949-57. PubMed ID: 3461071
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.